Blood Podcast
By American Society of Hematology
Listen to a podcast, please open Podcast Republic app. Available on Google Play Store and Apple App Store.
Image by American Society of Hematology
Category: Science
Open in Apple Podcasts
Open RSS feed
Open Website
Rate for this podcast
Subscribers: 26
Reviews: 0
Episodes: 328
Description
The Blood Podcast summarizes content recently published in Blood, the most cited peer-reviewed publication in the field of hematology.
| Episode | Date |
|---|---|
|
A novel mouse model of sickle cell SC disease; multiple myeloma induction therapy with isatuximab, carfilzomib, lenalidomide, and dexamethasone; and splicing factor mutations in myelodysplastic syndromes
|
Jul 03, 2025 |
|
An AI model for transplant risk in myelofibrosis; preventing priapism in men with sickle cell anemia; hallmarks of T cell exhaustion absent in newly diagnosed MM
|
Jun 26, 2025 |
|
Social determinants of health and access to allogeneic hematopoietic cell transplantation, megakaryocyte growth factor receptor-based pretransplant conditioning for ex vivo autologous gene therapy, and novel protein biomarkers for risk stratification in a
|
Jun 23, 2025 |
|
Aggressive non-Hodgkin lymphoma: defining and managing high-risk subsets
|
Jun 19, 2025 |
|
A key role for T-cell TET3 in chronic GVHD; a BTK inhibitor for ITP; co-inhibition of pre-TCR and IL-7R pathways in a T-ALL patient subset
|
Jun 12, 2025 |
|
Special Episode: Eliminating the Need for Sequential Confirmation of Response in Multiple Myeloma
|
Jun 10, 2025 |
|
How I Treat Series on Geriatric Hematology
|
Jun 05, 2025 |
|
Single cell multi-omic analysis of leukemia stem cells, cyclophosphamide for non-immune effector cell-associated neurotoxicity, and glycosylation as a mediator of von Willebrand factor clearance
|
Jun 05, 2025 |
|
New insights on PU.1-mutated agammaglobulinemia; venetoclax-based induction therapy in younger AML patients; the link between ABO Blood groups and risk of future VTE
|
May 29, 2025 |
|
How I Treat Transfusion Medicine (part 2)
|
May 22, 2025 |
|
Clonal hematopoiesis in frequent blood donors, immune microenvironment and bispecific antibody response in diffuse large B-cell lymphoma, and blinatumomab as part of early consolidation therapy in CD19-positive Ph-negative B-cell acute lymphoblastic lymphoma
|
May 22, 2025 |
|
How I Treat Transfusion Medicine (part 1)
|
May 15, 2025 |
|
Discontinuing lenalidomide maintenance in MM; congenital neutropenia syndrome linked to COPZ1 mutations; low GVHD rates with ruxolitinib after allogeneic HCT
|
May 15, 2025 |
|
Measurable residual disease and maintenance therapy in acute myeloid leukemia (AML), stemness and chemotherapy resistance in AML, and effects of babesiosis on red blood cells in sickle cell disease
|
May 08, 2025 |
|
Uniquely programmed blood stem cells in the human lung; inclusive molecular classifier for DLBCL; new insights on NETs in the liver vasculature
|
May 01, 2025 |
|
Phosphoseryl-tRNA kinase inhibition in acute myeloid leukemia (AML), APOE gene variants and post-hematopoietic stem cell transplant outcomes in AML, and the role of chronic inflammation in sickle cell cardiomyopathy
|
Apr 24, 2025 |
|
How I Treat Myeloproliferative Neoplasms
|
Apr 17, 2025 |
|
The decline of transplant for relapsed myeloma; DDAVP response in bleeding disorders; dual DOT1L/EZH2 targeting in DLBCL
|
Apr 17, 2025 |
|
Interleukin-1 signaling pathways in myelodysplastic syndromes, the immune checkpoint regulator VISTA as a target in graft-vs-host disease, and epcoritamab plus chemotherapy in transplant-ineligible relapsed/refractory diffuse large B-cell lymphoma
|
Apr 10, 2025 |
|
Aging platelets shift to proinflammatory function; Odronextamab bispecific antibody therapy after CAR T in DLBCL; prizlon-cel, a novel bispecific CAR T, in B-NHL
|
Apr 03, 2025 |
|
Blood Bonus Episode: What is a Blood group?
|
Mar 31, 2025 |
|
Itacitinib in haploidentical hematopoietic cell transplantation, diagnosis and management of purpura fulminans, and lack of evidence for sickle cell crisis-associated mortality in individuals with sickle cell trait
|
Mar 27, 2025 |
|
Time-limited triplet therapy in relapsed/refractory CLL; patient-reported outcomes in chronic GVHD-related sclerosis; myeloid bias mechanisms in hematopoiesis
|
Mar 20, 2025 |
|
Azacitidine plus venetoclax in high-risk myelodysplastic syndromes, post-CAR T-cell hematotoxicity in B-cell acute lymphoblastic leukemia (B-ALL), and inotuzumab ozogamicin resistance in B-ALL
|
Mar 13, 2025 |
|
Mutations in AMBRA1 aggravate β-thalassemia; targeting MYD88 mutations in lymphomas; air pollution and incident VTE risk
|
Mar 06, 2025 |
|
Hypercalcemia in monoclonal gammopathy of undetermined significance, neutrophil gelatinase-associated lipocalin in hemostasis, and CD19-targeted NK- or T-cell therapy combined with anti-CD19 monoclonal antibodies
|
Feb 27, 2025 |
|
Review Series on a Quarter Century of TKIs in CML
|
Feb 27, 2025 |
|
A “belt and suspenders” approach to PNH; oral pathogens exacerbate chronic GVHD; microbial metabolome changes may adversely impact CAR-T outcomes
|
Feb 21, 2025 |
|
Mosunetuzumab in relapsed/refractory follicular lymphoma, CD70 CAR T-cells and an anti-CD33/anti-CD3 bispecific antibody in acute myeloid leukemia, and ferroptosis in stored red blood cells
|
Feb 13, 2025 |
|
Review Series on Basic/Translational Science of Factor VIII, Factor IX, and von Willebrand Factor
|
Feb 13, 2025 |
|
Dual TKI targeting in Ph+ ALL; role of liver endothelial ferroportin in iron sensing and homeostasis; severe anemia in pregnant patients with beta-thalassemia minor
|
Feb 06, 2025 |
|
First-line zanubrutinib, obinutuzumab, and venetoclax in mantle cell lymphoma; hyperdiploidy in multiple myeloma; and pegcrisantaspase plus venetoclax in relapsed/refractory acute myeloid leukemia
|
Jan 30, 2025 |
|
Targeting C3 in autoimmune hemolytic anemias; venetoclax testing to predict AML response; an improved understanding of the structure of FXIII complex
|
Jan 23, 2025 |
|
Review Series on Globin Disorders
|
Jan 23, 2025 |
|
Brentuximab vedotin, nivolumab, and chemotherapy in classical Hodgkin lymphoma; type 1 interferon signaling in sickle cell disease; and type 1 human leukocyte antigen gene mutations in cutaneous T-cell lymphoma
|
Jan 16, 2025 |
|
Iron overload aggravates MDS pathophysiology; long-term outcomes after TPO-RA treatment in ITP; new insights into APL treatment outcomes by age and risk
|
Jan 09, 2025 |
|
Dexamethasone dosing in newly diagnosed multiple myeloma, a new experimental model of X-linked sideroblastic anemia, and ciltacabtagene autoleucel in real-world myeloma treatment
|
Jan 02, 2025 |
|
Comparing BTK inhibitors in relapsed/refractory CLL; unraveling the genetic background of the AnWj-negative blood type; rapid adaptation of CLL cells to venetoclax
|
Dec 26, 2024 |
|
Primary resistance to BCMA-targeted bispecifics in multiple myeloma, emapalumab therapy in hemophagocytic lymphohistiocytosis, and chemotherapy-induced pyroptosis as a mechanism of thrombus formation in patients with cancer
|
Dec 19, 2024 |
|
Unravelling follicular lymphoma subtypes; stroke rate trends in sickle cell disease; procoagulant platelet activation promotes venous thrombosis
|
Dec 12, 2024 |
|
Clonal hematopoiesis in patients with telomere biology disorders, genomic alterations in extracutaneous juvenile xanthogranulomas, and the BCMA-CD3 bispecific antibody teclistamab in relapsed/refractory multiple myeloma
|
Dec 05, 2024 |
|
Targeting mutant calreticulin in MPNs; focusing on bleeding risk in patients with cancer; revisiting diagnostic guidelines for familial HLH
|
Nov 28, 2024 |
|
Review Series on T-Cell Lymphoma
|
Nov 21, 2024 |
|
Stratifying risk in acute myeloid leukemia, daratumumab plus chemotherapy in relapsed-refractory pediatric leukemias, and a method for creating genetically engineered platelets
|
Nov 21, 2024 |
|
Exploring the ecosystem of extramedullary myeloma; role of ruxolitinib for pediatric acute GvHD; “YAP”-ing about YAP1 and thrombopoiesis in ITP
|
Nov 14, 2024 |
|
First-line asciminib for chronic myeloid leukemia, a new risk score for clonal cytopenia, and genotyped D-positive blood transfusion in sickle cell anemia
|
Nov 07, 2024 |
|
Update on fixed-dose venetoclax-obinutuzumab in previously untreated CLL; dual epi-immunotherapy in cHL; predicting treatment failure in TKI-treated CML
|
Oct 31, 2024 |
|
Bone marrow failure related to ERG insufficiency, factor 11 in vascular hyperpermeability, and new criteria for evaluating anemia in myelofibrosis
|
Oct 24, 2024 |
|
Platelet glycoprotein receptor VI in abdominal aortic aneurysms, TP53 mutations in 5q-deleted myelodysplastic syndrome, and immunostimulatory cytokine plus CAR T-cell therapy in acute lymphoblastic leukemia
|
Oct 17, 2024 |
|
Using NGS to refine risk stratification in T-ALL; a novel gene therapy approach in severe α-thalassemia; molecular taxonomy of MDS
|
Oct 10, 2024 |
|
A novel tripartite fusion drives treatment resistance in atypical APL; managing iTTP without TPE; hope for motherhood after allogeneic HCT
|
Oct 03, 2024 |
|
Pirtobrutinib plus venetoclax with or without rituximab in relapsed/refractory CLL; murine models of erythroid 5ALA synthesis disorders; targeting PKCa in diabetes and hemochromatosis
|
Sep 26, 2024 |
|
Transplant outcomes in pediatric Fanconi anemia; hepatic Foxo1 regulates iron homeostasis; clinical networks improve APL outcomes in Latin America
|
Sep 19, 2024 |
|
CD8+ T-cell differentiation and treatment response in AML; ATM germline pathogenic variants affect cancer outcomes in ataxia-telangiectasia; efficacy of a selective menin-KMT2A inhibitor in KMT2A- and NPM1-altered leukemias
|
Sep 12, 2024 |
|
TCR-T cells for post-HCT leukemia recurrence; platelets are the predominant source of procoagulant membranes in hemostasis; BR + R maintenance for MCL
|
Sep 05, 2024 |
|
Outcomes of younger patients with mantle cell lymphoma; M-protein assessment during maintenance therapy in multiple myeloma; in vivo CAR T-cell generation using lentiviral vectors
|
Aug 29, 2024 |
|
Review Series on Factor XI
|
Aug 29, 2024 |
|
Protective role of neonatal CMV infection in B-ALL; GVHD targets organoid-forming bile duct stem cells; seven-year outcomes for venetoclax-ibrutinib therapy in MCL
|
Aug 22, 2024 |
|
Iron, HFE haemochromatosis, and infections; bispecific antibodies improve CAR T-cell response; determinants of outcome in NPM1-mutated AML
|
Aug 15, 2024 |
|
Immune fitness and response to taclistamab in R/R multiple myeloma; BCR::ABL1 M244V mutation causes resistance to asciminib; HSCT and myocardial fibrosis in young patients with SCD
|
Aug 08, 2024 |
|
Decitabine in older patients with AML; EPCR and sickle chronic kidney disease; lymphocyte depletion versus post-transplant cyclophosphamide for mismatched donor transplant for inborn errors of immunity
|
Aug 01, 2024 |
|
Impact of MRD-negative on PFS in myeloma; IPSS-R down-staging before transplant in MDS; hereditary angioedema and venous thromboembolism
|
Jul 25, 2024 |
|
Acalabrutinib, venetoclax and obinutuzumab in relapsed/refractory CLL; alternative donor transplantation for severe aplastic anemia; clonal relapse dynamics in AML following allogeneic HCT
|
Jul 18, 2024 |
|
Clinical impact of CRh in AML; thrombosis features in a real-life PNH cohort; and restriction of SOX11 expression to EBV-negative Burkitt lymphomas
|
Jul 11, 2024 |
|
Mutational and transcriptional landscape of pediatric BCP lymphoblastic lymphoma; the role of platelet-derived TGF-1 in immune thrombocytopenia; phase 3 trial of mavorixafor in WHIM syndrome
|
Jul 04, 2024 |
|
GM-CSF coordinates shelter in the cytokine storm; Interleukin-1 as a therapeutic target in TTP; CAR T-cell outcomes across race and ethnicity in LBCL
|
Jun 27, 2024 |
|
Review Series on Oncogenic Signaling and Immune Evasion in Hematologic Malignancies
|
Jun 27, 2024 |
|
Reassessing the CLL prognostic index; ADAMTS13 conformation and risk of relapse in immune-mediated TTP; haploidentical bone marrow transplant in sickle cell disease
|
Jun 20, 2024 |
|
A biomarker for disease severity in Wiskott-Aldrich Syndrome; loss of Dnmt3a confers resistance to IFNα; unrelated donor selection in HSCT with PTCy
|
Jun 13, 2024 |
|
Nilotinib with or without cytarabine for Philadelphia-positive AML; thrombosis risk in Factor V Leiden and Prothrombin G20210A; ctDNA improves prognostic prediction in relapsed/refractory multiple myeloma
|
Jun 06, 2024 |
|
Hemophilia prophylaxis with fitusiran vs BPA/CFC; germline NBN variants in pediatric B-ALL; Histone demethylation and cell-intrinsic immune response in AML
|
May 30, 2024 |
|
Effects of voxelotor on cerebral blood flow in pediatric sickle cell disease; thrombosis in Vexas syndrome; response to tyrosine kinase inhibitors in ABL-class acute lymphoblastic leukemia
|
May 23, 2024 |
|
Stamping out high-risk myeloma with D-KRd and tandem transplant; plasmin-cleaved VWF in microthrombosis; SCD plasma sensitizes iPSC-derived sensory neurons
|
May 16, 2024 |
|
Allogeneic transplant in first remission for post-induction molecular MRD; circulating HSPCs actively participate in human hematopoiesis; let-7 miRNAs repress HIC2 to regulate BCL11A transcription and hemoglobin switching
|
May 09, 2024 |
|
ADAMTS13 recovery in caplacizumab-treated TTP; inhibition of venetoclax-resistant BCL2 variants with sonrotoclax; genomic insights from Castleman disease in twins
|
May 02, 2024 |
|
Durable response after tisa-cel in adults with relapsed/refractory follicular lymphoma; high microRNA-145 plasma levels indicate decreased risk of VTE; epigenetic/immunogenetic signature in the prediction of outcomes for high-count monoclonal B lymphocytosis
|
Apr 25, 2024 |
|
Gut microbiota exploitation by CPX-351 in AML; optimizing anti-myeloma immunity for ASCT; which pediatric ITP patients will develop lupus?
|
Apr 18, 2024 |
|
Jak2V617F clonal hematopoiesis promotes arterial thrombosis; Staphylococcus aureus infection in Sézary syndrome; clinical features of RAC2-related immunodeficiency
|
Apr 13, 2024 |
|
Molecular mimicry in aplastic anemia; emicizumab prophylaxis in infants with hemophilia; hydroxyurea reduces infections in SCA
|
Apr 04, 2024 |
|
Review Series on the Influence of the Tumor Microenvironment on the Pathogenesis of B-Cell Lymphomas
|
Mar 28, 2024 |
|
Free light chain mass spectrometry in diagnosis and monitoring of AL amyloidosis; T cells of AML patients in remission have distinct RNA signatures; and protective effect of ADAMTS13 in sickle cell mice depends on von Willebrand factor clearance
|
Mar 28, 2024 |
|
Eculizumab in transplant-associated thrombotic microangiopathy; reclassifying malignant monocytosis; targeting tissue factor in antiphospholipid syndrome
|
Mar 21, 2024 |
|
Identification of rare relapse-initiating stem cells post-transplantation; interferon α impairs erythropoiesis in sickle cell disease; TNFα promotes clonal dominance of KIT D816V+ cells in mastocytosis
|
Mar 14, 2024 |
|
How PAR2 signaling drives thrombo-inflammation; pretransfusion hemoglobin levels linked to survival in beta-thalassemia; etoposide is better than its reputation in primary HLH
|
Mar 07, 2024 |
|
Brentuximab vedotin plus dacarbazine or nivolumab in classical Hodgkin lymphoma; loss of CD20 causes resistance to mosunetuzumab in r/r B-cell lymphomas; trogocytosis as a driver of RBC antigen loss
|
Feb 29, 2024 |
|
CAR T cells plus ibrutinib in relapsed/refractory MCL; targeting SGF29 in AML; diffusion-limited oxygen release from stored blood
|
Feb 22, 2024 |
|
Long-term outcomes of pulmonary embolism in children and adolescents; hereditary angioedema caused by a methionine-379 to lysine substitution in kininogens; predictors of loss of MRD negativity in multiple myeloma
|
Feb 15, 2024 |
|
Extended follow-up of axi-cel in indolent NHL; platelets help clear senescent RBCs; novel risk stratification strategy for CNS lymphoma
|
Feb 08, 2024 |
|
Lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma; reciprocal stabilization of coagulation factor XIII-A and -B subunits; inotuzumab ozogamicin for MRD in ALL
|
Feb 01, 2024 |
|
Maternal anticancer drug exposure and leukemia; PIEZO1-TMEM16F coupling in hereditary xerocytosis; NPM1 MRD during venetoclax therapy in NPM1-mutated AML
|
Jan 25, 2024 |
|
TCRαβ/CD19-cell depleted haploHSCT for pediatric leukemia; malignancy-associated hemophagocytic lymphohistiocytosis in Sweden; the bone marrow as the primary site of thrombopoiesis
|
Jan 18, 2024 |
|
Fibrin polymerization and thrombosis; preventing CD19-negative relapse after CAR T-cell therapy in ALL; and impact of aberrant FUS condensates on HSC aging
|
Jan 11, 2024 |
|
CD24Fc for prevention of GVHD; origins of active EBV disease; the role of PF4 in platelet activation
|
Jan 04, 2024 |
|
Profiling a new VITT-like disorder; real-world outcomes of tafasitamab and lenalidomide in LBCL; and spatial mapping of human hematopoiesis
|
Dec 28, 2023 |
|
A natural history of familial platelet disorder with myeloid malignancy; HEXIM1 as an essential transcription regulator in erythropoiesis; residual disease predicts relapse in CML patients
|
Dec 21, 2023 |
|
ETP and MRD for risk assessment in T-ALL; allogeneic HCT outcomes in CGD; effects of pathogenic/likely pathogenic variants in inherited hemostasis disorders
|
Dec 14, 2023 |
|
Sorafenib plus intensive chemotherapy in newly diagnosed FLT3-ITD AML; inhibition of PLK4 in TP53-mutated AML; the role of CD44 in Plasmodium falciparum infection
|
Dec 07, 2023 |
|
High-risk cytogenetics in solitary bone plasmacytomas; complement activation in vaso-occlusive pain episodes; platelet reactivity to predict thrombotic disease risk
|
Nov 30, 2023 |
|
Very long-term follow-up of FCR therapy for CLL, risk assessment of KMT2A-rearranged B-cell precursor ALL in adults; anti-myeloma therapy using antibodies armed with B-BiTEs
|
Nov 23, 2023 |
|
Fractionated gemtuzumab ozagamicin Dosing in Elderly AML Patients; Loss-of-function of ENT3 drives histiocytosis; Alternative splicing of CD20 5’-UTR in B-lymphomas
|
Nov 16, 2023 |
|
Review Series on RNA Therapeutics in Hematology
|
Nov 14, 2023 |
|
Prognostic significance of splicing factor gene mutations in AML; therapy resistance in multiple myeloma; the effects of KIT ligand deletion on HSC homeostasis
|
Nov 09, 2023 |
|
Targeting prostacyclin to inhibit platelet activation; MRD-tailored myeloma maintenance; AREG and HSC function in DNA damage repair deficiency and aging
|
Nov 02, 2023 |
|
Lenalinomide plus rituximab for elderly patients with DLBCL, platelet GP6-mediated neutrophil recruitment in acute lung injury, and the role of AXL3 in mantle cell lymphoma.
|
Oct 26, 2023 |
|
Gut microbiota diversity and mortality in pediatric allo-HSCT; C5 inhibition in atypical HUS; and pembrolizumab plus vorinostat in PD-1-refractory Hodgkin lymphoma
|
Oct 19, 2023 |
|
IL-15 inhibitor BNZ-1 is safe and effective in T-cell LGLL, gene therapy trial for Wiskott-Aldrich syndrome, and ethical framework to select patients for CAR T-cell therapy
|
Oct 12, 2023 |
|
DDX41 gene variant prevalence and AML/MDS risk, VITAL mAb treatment of light chain amyloidosis, and movement/neurocognitive toxicities after BCMA CAR T cell treatment
|
Oct 05, 2023 |
|
IL-7 receptor signaling in B-cell differentiation, venetoclax plus obinutuzumab in older patients with CLL, LDL promotes microvascular thrombosis via von Willebrand Factor
|
Sep 28, 2023 |
|
Real-world CAR T therapy in older DLBCL patients, monoclonal antibody blocking APC for hemophilia therapy, and targeting the epichaperome in AML
|
Sep 21, 2023 |
|
Obinutuzumab, ibrutinib, and venetoclax in untreated CLL with deletion(17p)/TP53 mutation; NOTCH2 mutants promote chemo-resistance in DLBCL; and the role of DBY/HLA class II complexes in chronic GVHD
|
Sep 14, 2023 |
|
Long-term outcomes with pembrolizumab in Hodgkin lymphoma, the “incredible ULK” alleviates β-thalassemia, and recommendations for managing CAR T hematotoxicity
|
Sep 07, 2023 |
|
How I Manage Inpatient Consultations for Quantitative Neutrophil Abnormalities in Adults
|
Aug 31, 2023 |
|
Dimethyl fumarate in cutaneous T-cell lymphoma, lipid nanoparticles for editing of human hematopoietic cells, and racial and geographic disparities in lymphoma trials
|
Aug 31, 2023 |
|
Detailed safety profile of acalabrutinib vs ibrutinib in CLL, inflammation in trauma-induced coagulopathy, abatacept exposure and acute GVHD risk
|
Aug 24, 2023 |
|
Pembrolizumab after ASCT in PTCL, germline predisposition to myeloid neoplasms in patients with hypoplastic bone marrow, and limited plasticity of monocyte fate and function
|
Aug 17, 2023 |
|
Review Series on Hematopoietic Stem Cells
|
Aug 10, 2023 |
|
WGS informs risk of follicular lymphoma transformation; resolvin D4 regulates neutrophil deployment; Hodgkin lymphoma-directed treatment for early-stage NLPHL
|
Aug 10, 2023 |
|
Ventricular arrhythmias in sickle cell anemia, molecular heterogeneity of pediatric lymphoproliferative disorders, the role of the bone marrow microenvironment in myeloid disorders
|
Aug 03, 2023 |
|
Silent infarcts in iTTP remission, a ZDHHC palmitoyltransferase regulates oxidative phosphorylation in AML, and hepatic sinusoid as a niche for ANKL
|
Jul 27, 2023 |
|
Poverty and relapse risk in children with ALL, eligibility and enrollment of diverse populations in myeloma trials, and clonal hematopoiesis in VEXAS syndrome
|
Jul 20, 2023 |
|
Pembrolizumab in PMBCL, allogeneic CD19 CAR T cells for pediatric B-cell ALL, and fetal iron overload in β-thalassemia
|
Jul 13, 2023 |
|
Gene therapy for WHIM syndrome, fate of hematopoietic stem cells after transplantation, and the role of C-terminal FGF23 peptides in iron conservation
|
Jul 06, 2023 |
|
Key role of hepcidin in polycythemia vera, signatures of CAR T cell dysfunction, and IL-34 as a novel AML therapy?
|
Jun 29, 2023 |
|
BMT as initial treatment for severe aplastic anemia, macrophage metabolic rewiring in sickle cell disease, and predicting outcomes using PET radiomics in diffuse large B cell lymphoma
|
Jun 22, 2023 |
|
End of the vincristine/steroid pulse era in pediatric ALL?, “trial and error” with abatacept in GVHD, and hemorrhage risk with dasatinib therapy
|
Jun 15, 2023 |
|
Prolonged response after stopping TPO-RA in ITP, TP53 mutations and myelofibrosis outcomes, clinical picture of ERCC6L2 disease, where variants predispose to marrow failure and malignancy
|
Jun 08, 2023 |
|
Hodgkin lymphoma outcomes in the novel agent era, genomic safe harbors for precision T cell engineering, and a transcriptomic atlas to map imatinib resistance in CML
|
Jun 01, 2023 |
|
Pembrolizumab plus AVD for classical Hodgkin lymphoma, targeting the CD40/CD40-ligand axis in Waldenström Macroglobulinemia, and CXCR4-expressing CAR-cytokine induced killer cells in AML
|
May 25, 2023 |
|
How I Treat Series: Emergent CAR T-Cell Toxicities
|
May 18, 2023 |
|
Specific CD8+ T cell clones in ITP, Refining DLBCL prognosis with the “dark-zone signature”, and rethinking the regenerative role of HSCs in acute hematopoietic emergencies
|
May 18, 2023 |
|
Tips for Trainees for a Career in Publishing with Drs. Nancy Berliner and Andrew Roberts
|
May 15, 2023 |
|
Axi-cel in refractory large B-cell lymphoma, effects of C1 inhibitor deficiency on coagulation, and the evolution of therapy-related myeloid neoplasms
|
May 11, 2023 |
|
Gut microbiota and outcomes in DLBCL, NFIA-ETO2 fusion cooperates with TP53 in leukemogenesis, and the impact of nirmatrelvir + ritonavir on CLL patient outcomes during the Omicron surge
|
May 04, 2023 |
|
Revised response criteria for high-risk MDS, machine learning guides diagnosis of bone marrow failure syndromes, and RhD-positive transfusions for Asian-type DEL patients with serologic RhD-negative typing
|
Apr 27, 2023 |
|
AIHA during pregnancy, rapid immune tolerance induction in severe hemophilia A, and aging changes control of HSC proliferation
|
Apr 20, 2023 |
|
Review Series on Classical Myeloproliferative Neoplasms
|
Apr 20, 2023 |
|
Factor H variants in paroxysmal nocturnal hemoglobinuria, the role of factor XII in SCD-related thrombosis, and clinical features of therapy-related NPM1-mutated AML
|
Apr 14, 2023 |
|
Lenalidomide and genetic profiling in myeloma, T-cell immunotherapy upregulates AML cell MHC-class II, and young fecal microbiota rejuvenate HSCs
|
Apr 06, 2023 |
|
Review Series on Germ Line Predisposition to Hematologic Malignancy
|
Mar 30, 2023 |
|
HLA-E-restricted immune response in EBV infection, the role of NRX-0492 in CLL, and NSAIDs for bone marrow failure in Ghosal Hematodiaphyseal Dysplasia
|
Mar 30, 2023 |
|
Anti-malaria benefit of hydroxyurea in SCA, IL-22 in the treatment in lower GI acute GVHD, and FLT3-ITD changes depend on context in AML
|
Mar 23, 2023 |
|
Single-cell genotyping of MDS/CMML clonal output, VTE risk in diffuse glioma, and Del(1p32) is an adverse prognostic factor in myeloma
|
Mar 16, 2023 |
|
RUNX1 isoform imbalance drives ML-DS, VWF-binding RNA aptamer for hemophilia A treatment, and EZH1/2 inhibitor valemetostat in relapsed/refractory ATL
|
Mar 09, 2023 |
|
Phase 3 trial of leniolisib in activated PI3Kδ syndrome, dabrafenib plus trametinib in relapsed/refractory hairy cell leukemia, and TγδLGL leukemia as a more symptomatic subset of leukemia
|
Mar 02, 2023 |
|
Review Series on Banked Allogeneic Immune Effector Cells
|
Feb 23, 2023 |
|
Hydroxyurea for secondary stroke prevention in SCD, mutant CALR as a rogue cytokine in MPNs, and parsing pathobiology in Burkitt lymphoma
|
Feb 23, 2023 |
|
HSCT for hypomorphic RAG deficiency, EBV-driven lymphoid neoplasms in pediatric ALL, and clonal hematopoiesis and recurrent vascular events in stroke patients
|
Feb 16, 2023 |
|
MRD dynamics during ixazomib maintenance in MM, disparities in CAR T-cell therapy for ALL, and BAX variants and resistance to BH3-mimetics in AML
|
Feb 09, 2023 |
|
Itacitinib monotherapy for GVHD, the role of ERG in EVI1-driven AML, and germline DDX41 mutations in myeloid neoplasms
|
Feb 02, 2023 |
|
Stem cell transplant for SCD normalizes brain blood flow, novel GALE variants disrupt platelet development, and revisiting risk classification in NPM1-mutant AML
|
Jan 26, 2023 |
|
Review Series on Single-Cell Genomics
|
Jan 26, 2023 |
|
Allogeneic transplantation in older and infirm AML patients, cilta-cel in progressive multiple myeloma, and anti-CD20 therapy in relapsed TTP
|
Jan 19, 2023 |
|
Piezo antigens define a new blood group system, enasidenib in mutant-IDH2 relapsed/refractory AML, and breakthrough COVID-19 despite prophylaxis in B-cell malignancies
|
Jan 12, 2023 |
|
Immune thrombocytopenia in pregnancy, ASCT in adults with inborn errors of immunity, and long-term health outcomes of childhood AML survivors
|
Jan 05, 2023 |
|
How I Treat Series: Management of High-risk Patients Following Allogeneic Transplant
|
Jan 05, 2023 |
|
IL-13/IL-4 signaling and fibrotic progression in myelofibrosis, VWF-targeted thrombolysis in acute ischemic stroke, and NK cell dysfunction in relapsed AML
|
Dec 29, 2022 |
|
Effects of iron repletion on donor RBC quality, long-term outcomes in relapsed/refractory hairy cell leukemia after vemurafenib, and off-the-shelf cryopreserved platelets for detecting HIT
|
Dec 22, 2022 |
|
Germline predisposition variants occur in all age groups in MDS, αβ-haplo-HCT excels in children with acute leukemias/MDS, and poor outcomes after CAR T cell failure in B-cell lymphomas
|
Dec 15, 2022 |
|
Predicting VTE in multiple myeloma, azithromycin promotes relapse after HSCT, and dual antigen targeted NK cells in B cell malignancies
|
Dec 08, 2022 |
|
Using MRD to guide CLL treatment intensity, donor NK cells boost immune reconstitution after haplo-BMT, and EZH2 drives retinoic acid resistance in variant APL
|
Dec 01, 2022 |
|
Tolerability of CD19 CAR T cells in lymphoma, causes of platelet spherocytosis, and using prebiotics to reduce GVHD
|
Nov 24, 2022 |
|
Transplant in adult Ph+ ALL, acalabrutinib and ventricular arrythmias, and antibody prevention of fetal/neonatal alloimmune thrombocytopenia
|
Nov 17, 2022 |
|
Restricting dietary methionine in AML, transferrin in high altitude-induced hypercoagulability, and LIF as protection against GVHD
|
Nov 10, 2022 |
|
Sickle hemoglobin activates monocytes via TLR4, germinal center B cells provide a niche for T-cell lymphoma, and a combination immunosuppression regimen for acquired hemophilia A
|
Nov 03, 2022 |
|
Lineage switching in MLL/AF4 leukemia, ibrutinib in mantle cell lymphoma with CNS relapse, and gilteritinib plus azacitidine in newly diagnosed FLT3-mutated AML
|
Oct 27, 2022 |
|
Lenalidomide and subsequent TP53-mutated myeloid neoplasms, abnormal uterine bleeding after VTE, and novel tri-specific antibody for B-ALL
|
Oct 20, 2022 |
|
Review Series on Megakaryopoiesis and Platelet Production
|
Oct 20, 2022 |
|
Prognostic impact of NPM1 and FLT3 mutations in AML, progression of monoclonal B cell lymphocytosis, and creating RBCs with rare blood types in the laboratory
|
Oct 13, 2022 |
|
Transplant outcomes in adults with immunodeficiencies and erythroblastic islands as niches for terminal erythropoiesis and granulopoiesis
|
Oct 07, 2022 |
|
Ticagrelor in pediatric sickle cell disease, UBA1 translation impacts severity of VEXAS syndrome, and T-cell immunity and chemotherapy response in ALL
|
Sep 29, 2022 |
|
Race affects treatment outcomes in iTTP, 2022 ELN AML recommendations, and a comprehensive MRD assessment in MCL
|
Sep 22, 2022 |
|
The International Consensus Classification: An interview with Drs. Daniel Arber and Elias Campo
|
Sep 15, 2022 |
|
Tranexamic acid prophylaxis in heme malignancies, N-glycosylation as a therapeutic vulnerability in CALR-mutant MPN, and myocardial fibrosis in sickle cell anemia
|
Sep 15, 2022 |
|
Rest alleviates T-cell exhaustion by bispecific antibodies, exercise vs desmopressin in mild hemophilia A, and targeting MDM2 to enhance antileukemia immunity after transplant
|
Sep 08, 2022 |
|
Sutimlimab vs placebo in cold agglutinin disease, the impact of etoposide versus auto-transplant in PTCL, and the role of pulmonary NETs in sickle cell disease
|
Sep 01, 2022 |
|
Rivaroxaban after cancer surgery, genetics and survival in severe aplastic anemia, and a 5-year follow up of rituximab-venetoclax in relapsed/refractory CLL
|
Aug 25, 2022 |
|
Stroke in hereditary TTP, and germline DDX41 variants as risk factors and prognostic markers in myeloid neoplasms
|
Aug 18, 2022 |
|
Cost effectiveness of first-line daratumumab in MM, base-edited CAR T cells for T-ALL, and the role of SETBP1 mutations in chronic neutrophilic leukemia
|
Aug 11, 2022 |
|
Immune thrombocytopenia and adenoviral SARS-COV2 vaccines, genomics, and a risk assessment model of anti-CD19 CAR T-cell treatment outcomes in lymphoma
|
Aug 04, 2022 |
|
Naturally selected CD7 CAR T cell therapy for T-lineage malignancies, CD4+ T cell exhaustion and PD-L1 inhibition in B-ALL, and tPA-induced phosphorylation of occludin in stroke
|
Jul 28, 2022 |
|
Role of PIEZO1 in leukocyte extravasation, CD8+ T-cell activation in macrophage activation syndrome, and ABO O blood group as a novel risk factor for HIT
|
Jul 21, 2022 |
|
Long-term ibrutinib-rituximab vs FCR in CLL, procoagulant platelet sentinels in prevention of inflammatory bleeding, and new SERPINC1 variants in thrombophilia
|
Jul 14, 2022 |
|
Malignancy risk from genetically modified immune effector cells, p53 immunohistochemistry as a new tool in AML, and phenotypic escape from CD19-directed immunotherapies.
|
Jul 07, 2022 |
|
Overcoming CAR T cell resistance in myeloma, why anti-CCR4 antibody therapy in CTCL sometimes fails, and corticosteroids increase risk of VOE in sickle disease
|
Jun 30, 2022 |
|
Salvage therapy with NICE for Hodgkin lymphoma, BMP2/SMAD pathway activation in leukemic transformation, and the role of zinc in T-cell reconstitution after HSCT
|
Jun 23, 2022 |
|
MRD and post-transplant outcomes in older AML patients, enhancer hijacking in a novel high-risk B-other ALL subtype, and ruxolitinib in pediatric HLH
|
Jun 16, 2022 |
|
Anti-PF4 antibodies after Covid vaccination, CAR T-cell therapy for CNS leukemia, and advances in Diamond-Blackfan anemia
|
Jun 09, 2022 |
|
Fixed-duration ibrutinib + venetoclax for CLL, aryl hydrocarbon receptor in idiopathic pneumonia syndrome, and VWF propeptide and multimerization
|
Jun 02, 2022 |
|
HEATR3 variants as a new cause of Diamond-Blackfan anemia, zanubrutinib in mantle cell lymphoma, and HMGB1 inhibits Epo signaling in anemia of inflammation
|
May 26, 2022 |
|
HLA-DQ heterodimers and transplantation, the genomic landscape of LGL leukemia, and an updated classification of hemochromatosis
|
May 19, 2022 |
|
Role of macrophage NOX2 in alveolar homeostasis, hydroxyurea versus peginterferon alfa-2a in high-risk PV and ET, and the emerging PV treatment landscape
|
May 12, 2022 |
|
Microbiome and CD4 T-cell recovery after allogeneic HCT, and a paradigm shift to CAR T-cells in the second line for large B-cell lymphoma?
|
May 05, 2022 |
|
Canakinumab in SCA, antigen-specific donor T-cells to prevent post-transplant relapse in ALL, and nasopharyngeal mucosal immunity defects in transplanted SCID patients
|
Apr 28, 2022 |
|
Timing (and utility) of CNS prophylaxis in DLBCL, Apollo deficiency in a bone marrow failure syndrome, and GATA1 mutants in congenital anemia
|
Apr 21, 2022 |
|
Obinutuzumab plus lenalidomide in advanced follicular lymphoma, mechanisms of anemia in children with malaria, and granulocyte microvesicles for septic shock
|
Apr 14, 2022 |
|
Structural racism and AML survival, promoter competition and hemoglobin switching, and CAR T-cell therapy and high-risk cytogenetics in ALL
|
Apr 07, 2022 |
|
Targeting the PBX1-FOXM1 axis in myeloma, SF3B1 mutations in MDS, and pulmonary artery hypertension-associated mortality in β-thalassemia patients
|
Mar 31, 2022 |
|
Novel high-risk subtypes in adult B-ALL, Liso-cel CAR-T therapy in CLL, and liquid biopsies in large B-cell lymphomas
|
Mar 24, 2022 |
|
Effective treatments for kaposiform hemangioendothelioma, causes of vascular dysfunction in sickle cell patients, and better strategies to select therapy in older adults with AML
|
Mar 17, 2022 |
|
COVID-19 vaccination in patients with blood cancers and recalibrating the HLA barrier in haploidentical stem cell transplantation
|
Mar 10, 2022 |
|
Cell therapy options for chemo-sensitive DLBCL, PIGA mutations in a novel subtype of hemochromatosis, and triplet combination therapy in high-risk CLL
|
Mar 03, 2022 |
|
Germline predisposition mutations in AML, a new way to resolve NETs, and venetoclax and BAX mutations in normal myeloid cells of CLL patients
|
Feb 24, 2022 |
|
Ovarian reserve in sickle cell anemia, genomic landscape of adult T-cell leukemia/lymphoma, and a new prognostic index for HLH-associated heme malignancies
|
Feb 17, 2022 |
|
Role of HBO1 in HSC function, robust MRD analysis in multiple myeloma, and cardiac ferroptosis in sickle cell disease
|
Feb 10, 2022 |
|
The ARID3A transcription factor suppresses leukemia, a COVID-19 booster shot benefits CLL patients, and advances in the genetics of congenital neutropenia
|
Feb 03, 2022 |
|
Sustained MRD negativity & outcomes in myeloma, therapeutic targeting of VWF in TTP, and improving CAR T-cells in CLL with PI3 kinase inhibition
|
Jan 28, 2022 |
|
Does route of CNS prophylaxis for DLBCL matter?, the connection between CHIP and COPD, and ATRA plus low-dose rituximab in ITP
|
Jan 20, 2022 |
|
A spectrum of ALK-positive histiocytosis, and metabolites as biomarkers for GvHD diagnosis and risk assignment
|
Jan 13, 2022 |
|
Long-term outcomes in severe aplastic anemia, cytoprotective effects of factor VIIa, and the role of IL-1 in hematopoietic stem cell ageing
|
Jan 06, 2022 |
|
CRISPR cure for XMEN disease?, JAK inhibition in T-cell lymphomas, and intracranial hemorrhage in hemophilia
|
Dec 30, 2021 |
|
Antigen presentation by platelet extracellular vesicles, fibril-reactive monoclonal antibody therapy for AL amyloidosis, and targeting gasdermin D in sepsis
|
Dec 23, 2021 |
|
Mesenchymal stromal cells in SCD, CAR T-cell-mediated hematotoxicity in B-cell lymphoma, and dual cytokine blockade in GVHD
|
Dec 16, 2021 |
|
PROTACs for JAKs in CRLF2-rearranged ALL, risk stratification in Down syndrome-associated leukemia, and how losing sialic acid activates immune cells in ITP
|
Dec 09, 2021 |
|
Belumosudil for chronic GVHD, mechanistic insights into VITT, and factors driving molecular response in IFNα-treated MPNs
|
Dec 02, 2021 |
|
Post-vaccination COVID-19 in patients with hematologic malignancies
|
Dec 01, 2021 |
|
Asciminib versus bosutinib in CML; dopamine signaling and hematopoietic stem cells; complement factor C5 and VTE risk
|
Nov 25, 2021 |
|
Danicopan add-on therapy in PNH, neural networks to identify bone marrow cells, and RNA editome and hematopoiesis
|
Nov 18, 2021 |
|
Machine learning in classification of AML, aging bone marrow in leukemia, and treating bleeding disorders of unknown cause
|
Nov 11, 2021 |
|
Anti-CD36-antibody therapy of neonatal alloimmune thrombocytopenia, costs of hemophilia B gene therapy, and insights into erythroid maturation
|
Nov 04, 2021 |
|
Genetic risks for CMV after BMT, multiplex gene editing to reactivate HbF, and rewiring plasma cells in light chain amyloidosis and myeloma
|
Oct 28, 2021 |
|
Omidubicel vs standard umbilical cord blood transplant, CAR T-cell associated lymphomas, and CD63 and ferritin export
|
Oct 21, 2021 |
|
Iron homeostasis and anemia of inflammation in TB, and long-term outcomes of gene therapy in adenosine deaminase-deficient SCID patients
|
Oct 14, 2021 |
|
Immune megakaryocytes, PD1 deletions in CTCL, and COVID-19 vaccine and VITT
|
Oct 07, 2021 |
|
Inhibition of P-selectin as an anticoagulant, prognostic implications of CEBPA mutations in AML, and treating sickle cell disease with voxelitor
|
Sep 30, 2021 |
|
Caution on JAK inhibitors in HLH, CD44 loss sensitizes AML to venetoclax, and new insights on cell cycle control in Richter transformation
|
Sep 23, 2021 |
|
Improved risk assessment in adult BCR-ABL1-negative B-ALL, value of clone metrics in clonal cytopenias, a placental protease generates a peptide to inhibit NET formation
|
Sep 16, 2021 |
|
Fixed-duration venetoclax in relapsed CLL, differing effects of invariant NK T cells, and under recognition of rare TERT variants in MDS
|
Sep 09, 2021 |
|
Activated BCL11B in acute leukemias, SARS-CoV-2 antibody responses in lymphoma patients receiving B-cell therapies, and PD-L1 in neutrophil apoptosis and tissue inflammation
|
Sep 02, 2021 |
|
IFN-λ therapy for GvHD, mechanism of decitabine in ITP, and TET2 mutations in chronic NK-LGL leukemia
|
Aug 26, 2021 |
|
Review Series on Mechanisms of Hematologic Malignancies
|
Aug 26, 2021 |
|
Choosing chemotherapy for older patients with AML, the role of the microenvironment in pediatric ALL, and efficacy of thrombopoietin receptor agonists in elderly patients with ITP
|
Aug 19, 2021 |
|
Brentuximab plus nivolumab in refractory/relapsed Hodgkin lymphoma, the signature of aging hematopoietic stem cells, and hepatocyte neogenin in iron homeostasis
|
Aug 12, 2021 |
|
Latest Research on the Intensity of AML Therapy in Older Patients, Platelets and T cell Activity in Sepsis, and Genotyping for CNS Lymphoma
|
Aug 05, 2021 |
|
Vaccine-induced Immune Thrombotic Thrombocytopenia
|
Jul 29, 2021 |
|
Latest research in post-transplant cyclophosphamide in matched unrelated versus haploidentical donors, outcomes in patients with AITL, and high molecular weight kininogen in acetaminophen-induced liver injury
|
Jul 22, 2021 |
|
Latest research in thrombosis in pediatric COVID-19, prognostic tool for very early stage CLL, and frontline treatment for newly diagnosed myeloma
|
Jul 15, 2021 |
|
Latest Research: Immunity to CMV, lymphoma microenvironment, and tPA induced bleeding
|
Jul 08, 2021 |
|
VEXAS: A Newly Identified Adult-onset Hemato-inflammatory Syndrome
|
Jul 01, 2021 |
|
Season 2, Episode 25
|
Jun 24, 2021 |
|
Season 2, Episode 24
|
Jun 17, 2021 |
|
Review Series on Platelets and Cancer
|
Jun 10, 2021 |
|
Season 2, Episode 23
|
Jun 10, 2021 |
|
Season 2, Episode 22
|
Jun 03, 2021 |
|
Season 2, Episode 21
|
May 27, 2021 |
|
Season 2, Episode 20
|
May 20, 2021 |
|
Season 2, Episode 19
|
May 13, 2021 |
|
Season 2, Episode 18
|
May 06, 2021 |
|
Season 2, Episode 17
|
Apr 29, 2021 |
|
Season 2, Episode 16
|
Apr 22, 2021 |
|
Season 2, Episode 15
|
Apr 15, 2021 |
|
Season 2, Episode 14
|
Apr 08, 2021 |
|
Season 2, Episode 13
|
Apr 01, 2021 |
|
Season 2, Episode 12
|
Mar 25, 2021 |
|
Season 2, Episode 11
|
Mar 18, 2021 |
|
Season 2, Bonus: How I Treat Series: Acquired Hemolytic Anemia
|
Mar 15, 2021 |
|
Season 2, Episode 10
|
Mar 11, 2021 |
|
Season 2, Episode 9
|
Mar 04, 2021 |
|
Season 2, Episode 8
|
Feb 25, 2021 |
|
Season 2, Episode 7
|
Feb 18, 2021 |
|
Season 2, Episode 6
|
Feb 11, 2021 |
|
Season 2, Episode 5
|
Feb 04, 2021 |
|
Season 2, Episode 4
|
Jan 28, 2021 |
|
Season 2, Episode 3
|
Jan 21, 2021 |
|
Season 2, Episode 2
|
Jan 14, 2021 |
|
Season 2, Episode 1
|
Jan 07, 2021 |
|
Season 1, Episode 52
|
Dec 24, 2020 |
|
Season 1, Episode 51
|
Dec 17, 2020 |
|
Season 1, Episode 50
|
Dec 10, 2020 |
|
Season 1, Episode 49
|
Dec 03, 2020 |
|
Season 1, Episode 48
|
Nov 26, 2020 |
|
Season 1, Episode 47
|
Nov 19, 2020 |
|
Season 1, Episode 46
|
Nov 12, 2020 |
|
Season 1, Episode 45
|
Nov 05, 2020 |
|
Season 1, Episode 44
|
Oct 29, 2020 |
|
Season 1, Episode 43
|
Oct 22, 2020 |
|
Season 1, Episode 42
|
Oct 15, 2020 |
|
Season 1, Episode 41
|
Oct 08, 2020 |
|
Review Series on Mechanisms and Clinical Implications of Clonal Hematopoiesis
|
Oct 01, 2020 |
|
Season 1, Episode 40
|
Oct 01, 2020 |
|
Season 1, Episode 39
|
Sep 24, 2020 |
|
Season 1, Episode 38
|
Sep 17, 2020 |
|
Review Series on Inherited Anemias
|
Sep 10, 2020 |
|
Season 1, Episode 37
|
Sep 10, 2020 |
|
Season 1, Episode 36
|
Sep 03, 2020 |
|
Season 1, Episode 35
|
Aug 27, 2020 |
|
Season 1, Episode 34
|
Aug 20, 2020 |
|
Season 1, Episode 33
|
Aug 13, 2020 |
|
Season 1, Episode 32
|
Aug 06, 2020 |
|
Season 1, Episode 31
|
Jul 30, 2020 |
|
Season 1, Episode 30
|
Jul 23, 2020 |
|
Season 1, Episode 29
|
Jul 16, 2020 |
|
Season 1, Episode 28
|
Jul 09, 2020 |
|
Season 1, Episode 27
|
Jul 02, 2020 |
|
Review Series on Secondary Leukemia
|
Jul 02, 2020 |
|
Season 1, Episode 26
|
Jun 25, 2020 |
|
Season 1, Episode 25
|
Jun 18, 2020 |
|
Season 1, Episode 24
|
Jun 11, 2020 |
|
Season 1, Episode 23
|
Jun 04, 2020 |
|
Season 1, Episode 22
|
May 28, 2020 |
|
Season 1, Episode 21
|
May 21, 2020 |
|
Season 1, Episode 20
|
May 14, 2020 |
|
Season 1, Episode 19
|
May 07, 2020 |
|
Season 1, Episode 18
|
Apr 30, 2020 |
|
Season 1, Episode 17
|
Apr 23, 2020 |
|
Review Series on Rare Systemic Hematologic Disorders
|
Apr 16, 2020 |
|
Season 1, Episode 16
|
Apr 16, 2020 |
|
Season 1, Episode 15
|
Apr 09, 2020 |
|
Season 1, Episode 14
|
Apr 02, 2020 |
|
Season 1, Episode 13
|
Mar 26, 2020 |
|
Season 1, Episode 12
|
Mar 19, 2020 |
|
Season 1, Episode 11
|
Mar 12, 2020 |
|
Season 1, Episode 10
|
Mar 05, 2020 |
|
Review Series on Understanding and Treating Primary Immunodeficiency
|
Feb 27, 2020 |
|
Season 1, Episode 9
|
Feb 27, 2020 |
|
Season 1, Episode 8
|
Feb 20, 2020 |
|
Season 1, Episode 7
|
Feb 13, 2020 |
|
Season 1, Episode 6
|
Feb 06, 2020 |
|
Review Series on Treatment of Venous Thrombotic Disorders
|
Jan 31, 2020 |
|
Season 1, Episode 5
|
Jan 30, 2020 |
|
Season 1, Episode 4
|
Jan 23, 2020 |
|
Season 1, Episode 3
|
Jan 16, 2020 |
|
Season 1, Episode 2
|
Jan 09, 2020 |
|
Season 1, Episode 1
|
Jan 02, 2020 |
|
Sneak Peek Episode 4
|
Dec 10, 2019 |
|
Sneak Peek Episode 1
|
Dec 10, 2019 |
|
Sneak Peek Episode 3
|
Dec 10, 2019 |
|
Sneak Peek Episode 2
|
Dec 10, 2019 |
|
Blood Podcast - Trailer
|
Nov 09, 2019 |